✉ Email this page to a colleague
« Back to Dashboard
Danirixin is an investigational drug.
There have been 10 clinical trials for Danirixin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 19th 2017.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].
There are twenty-eight US patents protecting this investigational drug and three hundred and forty-seven international patents.
Recent Clinical Trials for Danirixin
|GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects||GlaxoSmithKline||Phase 1|
|Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Phase 2|
|A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Phase 2|
Top disease conditions for Danirixin
Top clinical trial sponsors for Danirixin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Danirixin||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Danirixin||See Plans and Pricing||Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators||Pfizer Inc. (New York, NY)||See Plans and Pricing|
|Danirixin||See Plans and Pricing||JAK inhibitors containing a 4-membered heterocyclic amide||THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)||See Plans and Pricing|
|Danirixin||See Plans and Pricing||Fused imidazo-piperidine JAK inhibitors||THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)||See Plans and Pricing|
|Danirixin||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Danirixin||See Plans and Pricing||Therapeutic compounds and compositions, and methods of use thereof||Genentech, Inc. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Danirixin||Australia||AU2017261372||2036-05-05||See Plans and Pricing|
|Danirixin||Canada||CA3023278||2036-05-05||See Plans and Pricing|
|Danirixin||China||CN107847398||2036-05-05||See Plans and Pricing|
|Danirixin||European Patent Office||EP3452003||2036-05-05||See Plans and Pricing|
|Danirixin||Hong Kong||HK1249728||2036-05-05||See Plans and Pricing|
|Danirixin||Japan||JP2019520866||2036-05-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|